Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Fojo Website

Antonio Tito Fojo, M.D., Ph.D.

Selected Publications

1)  Fojo T, Bates S.
Mechanisms of resistance to PARP inhibitors--three and counting.
Cancer Discov. 3: 20-3, 2013.
2)  Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, Prchal JT, Tischler AS, Lechan RM, Zhuang Z.
New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia.
J. Clin. Oncol. [Epub ahead of print], 2013.
3)  Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Cell Rep. 3: 277-81, 2013.
4)  Komlodi-Pasztor E, Sackett DL, Fojo T.
Tales of how great drugs were brought down by a flawed rationale--response.
Clin. Cancer Res. 19: 1304, 2013.
5)  Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE.
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Oncologist. 17: 512, 2012.
6)  Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
Clin. Cancer Res. 18: 2374-81, 2012.
7)  Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B.
Combination chemotherapy in advanced adrenocortical carcinoma.
N. Engl. J. Med. 366: 2189-97, 2012.
8)  Fojo T, Bates S, Chabner BA.
Editor's Note ...Clinical Trial Reports: A New Section.
Oncologist. 17: 11-2, 2012.
9)  Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K.
False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Endocr. Relat. Cancer. 19: 83-93, 2012.
10)  Blagoev KB, Wilkerson J, Fojo T.
Hazard ratios in cancer clinical trials--a primer.
Nat Rev Clin Oncol. 9: 178-83, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 4/9/2013.